Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06058520 · ClinicalTrials.gov registry record · Early Phase 1
Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa
A Early Phase 1 study of Hidradenitis Suppurativa, sponsored by University of Minnesota.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT06058520 is a Early Phase 1 study of Hidradenitis Suppurativa that is actively recruiting participants, run by University of Minnesota. The registered enrollment target is 16 participants, below the 598-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06058520, a Early Phase 1 study of Hidradenitis Suppurativa, is actively recruiting participants, sponsored by University of Minnesota.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
HS is relatively common in the United States with a prevalence of 0.1-1.0%. 1 HS has a dramatic impact on quality of life, significantly more so than other chronic skin diseases, such as psoriasis or atopic dermatitis (AD). HS also has a large economic impact, due to frequent emergency department and inpatient care utilization, and re-hospitalization rates similar to congestive heart failure. Unfortunately, few treatment options are effective. There are currently three FDA-approved treatments for HS, including adalimumab, secukinumab, and bimekizumab, each with only 40- 60% respond to treatment and over 50% lose response within one year . The overarching goal of this pilot study is to investigate the central hypothesis that oral microbiota transplant therapy(MTT) alters the gut microbiome in patients with Hidradenitis Suppurativa (HS), influencing cutaneous microbiota via systemically absorbed gut-derived metabolites.
Conditions Studied
Interventions
- DRUG Fecal Microbiota - lyophilized
- DRUG Placebo drug
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-10-01 |
| Est. Completion | 2026-09-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06058520
The ClinicalTrials.gov registry entry for NCT06058520 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 598-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (97% lower). The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 2 interventions - of which Fecal Microbiota - lyophilized is the first listed.
NCT06058520 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT06058520 about?
NCT06058520 is a clinical study titled "Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa". HS is relatively common in the United States with a prevalence of 0.1-1.0%. 1 HS has a dramatic impact on quality of life, significantly more so than other chronic skin diseases, such as psoriasis or atopic dermatitis (AD). HS also has a large economic impact, due to frequent emergency department an...
What is the current status of trial NCT06058520?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 16 participants. The study started on 2023-10-01. Estimated completion is 2026-09-01.
What conditions does trial NCT06058520 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
What interventions are being tested in trial NCT06058520?
The interventions under investigation include: Fecal Microbiota - lyophilized (DRUG), Placebo drug (DRUG).
Who is sponsoring clinical trial NCT06058520?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06058520 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Open-label, Time-lagged, Dose-escalation Study to Evalaute the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.
RECRUITING · Early Phase 1
-
Aviclear for Hidradenitis Suppurativa (HS)
RECRUITING · NA
-
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
RECRUITING · Phase 2
-
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
RECRUITING · Phase 1
-
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
RECRUITING · Phase 3
-
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.